Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024. Details for the panel session are as follows: Title: A Revival in Neuro TherapeuticsSession Date and Time: Tuesday, October 1 from 2:15 – 3 PM EDT Location: The Westin Boston Seaport District About CerevanceCerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Utilizing a large and growing repository of over 15,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor symptoms of Parkinson’s disease and may also have disease-delaying effects. CVN766 is a potent and highly selective antagonist of the orexin 1 receptor which may benefit various psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel blocker of potassium efflux in glia, regulating the inflammasome in individuals living with neurodegenerative diseases. Cerevance’s robust pipeline aims to transform the lives of patients affected by CNS diseases. Contacts Cerevance:Johnna Simoes, [email protected] Media:Andrew Mielach, [email protected], +1-646-876-5868